• Novo Nordisk submitted once-daily etavopivat for FDA and EMA approval to treat sickle cell disease in patients aged 12 and older.
• Regulatory decisions are expected in 2027.
• Phase 3 results showed a 27% reduction in vaso-occlusive crises versus placebo, with approximately four months longer until the first crisis.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Novo Nordisk A/S published the original content used to generate this news brief on November 13, 2026, and is solely responsible for the information contained therein.